The 9th International Neoantigen Summit returns to Amsterdam over 21st-23rd July to bring together the only dedicated forum for end-to-end neoantigen development. From validation and identification to clinical readouts, biomarker strategy, personalised and off-the-shelf approaches – this is your only platform dedicated to sharing critical developments in neoantigen therapies.
This highly focused conference unites all the key players in the neoantigen field from Europe and US across biotech and pharma organisations. It brings together a seniority of 30%+ C-suite alongside directors, heads and scientists focused on cancer immunotherapy, clinical & preclinical development, antigen discovery and validation, bioinformatics and regulatory considerations. All of them share the goal of developing neoantigen‑targeted therapies – making this conference a must‑attend.
In a unique position to unite all the key players in the neoantigen industry, this summit sits at the heart of the neoantigen industry, making every conversation relevant and every connection intentional.
Over 3 jam-packed days of content, you can expect to:
- Gain the latest clinical data updates from companies like: Transgene, CellVax Therapeutics, Geneos Therapeutics and more
- Maximise bioinformatics and AI to improve neoantigen validation with companies like Evaxion and Khosen Bio
- Hear from 6 brand-new speaking companies including Black Canyon Bio, CellVax Therapeutics, Echo Immune, Epitopea, Khosen Bio, and Treos Bio
- Analyse preclinical data to better move through the clinic
…and much more! This conference is your one-stop-shop for all things neoantigen therapy.
Contact info:
Email: info@hansonwade.com
Phone:
UK: +44 (0)20 3141 8700
US: +1 617 455 4188